GlobeNewswire Inc | Oct 28, 2020 07:00AM EDT

October 28, 2020

PETAH TIKVA, Israel, Oct. 28, 2020 (GLOBE NEWSWIRE) -- PolyPid Ltd.(Nasdaq: PYPD), a Phase 3 clinical-stagebiopharmaceutical company focused on developing targeted, locally administered and prolonged-release therapeutics using its proprietary PLEX technology, today announced that it will report its third quarter 2020 financial results and operational highlights before the open of the U.S. financial markets onWednesday, November 11, 2020. The Company will host a conference call and webcast at 8:30 AM Eastern Timeto discuss the results and provide an update on business operations.

Conference Call Dial-In & Webcast Information:

Date: Wednesday, November 11, 2020Time: 8:30 AM Eastern TimeUnited States: +1 877 870 9135Israel: +972 1809 213-985International: +44 (0) 2071 928338Conference ID: 4557195Webcast: https://edge.media-server.com/mmc/p/u49mfor4

AboutPolyPidPolyPidis a Phase 3 clinical-stage biopharmaceutical company focused on developing targeted, locally administered and prolonged-release therapeutics using its proprietary PLEX (Polymer-Lipid Encapsulation matriX) technology. PolyPids product candidates are designed to address diseases with high unmet medical needs by pairing PLEX with drugs to deliver them directly to precise sites in the body at predetermined release rates and over durations ranging from several days to several months. PolyPids lead product candidate, D-PLEX100, is in Phase 3 clinical trials for the prevention of SSIs in different type of surgeries, including abdominal and open-heart surgery. PolyPids technology and products are based on the inventions of Dr.Noam Emanuel, the Founder and the Chief Scientific Officer of the company.

For additional company information, visitwww.polypid.com.

Forward-looking StatementsThis press release contains projections and other forward-looking statements regarding future events or our future financial performance. All statements other than present and historical facts and conditions contained in this release are forward-looking statements (within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended). These statements are only predictions and reflect our current beliefs and expectations with respect to future events and are based on assumptions and subject to risk and uncertainties and subject to change at any time. Actual events or results may differ materially from those contained in the projections or forward-looking statements. Forward-looking statements in this release are made pursuant to the safe harbor provisions contained in the Private Securities Litigation Reform Act of 1995. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release.PolyPidis not responsible for the contents of third-party websites.

Contacts:PolyPid, Ltd.Dikla Czaczkes AkselbradEVP & CFOTel: +972-747195700

Investors:Bob YedidLifeSci Advisors646-597-6989Bob@LifeSciAdvisors.com